4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
4D Molecular Therapeutics (NASDAQ: FDMT) will present at the 44th Annual J.P.
Rhea-AI Summary
4D Molecular Therapeutics (NASDAQ: FDMT) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan 14, 2026. The presentation is scheduled for 7:30 a.m. PT and will be available via webcast.
Members of 4DMT management will be available for one-on-one meetings. An archived copy of the webcast will be available for up to one year in the company’s Investors events section at the investor website.
Details
News Market Reaction – FDMT
On Dec 8, the day this news came out, FDMT closed 3.55% above the previous close.
Data tracked by StockTitan Argus for the Dec 8 session.
Key Figures
- Presentation date
- Jan 14, 2026
- J.P. Morgan Healthcare Conference schedule
- Presentation time
- 7:30 a.m. PT
- J.P. Morgan Healthcare Conference schedule
- Webcast availability
- Up to one year
- Archived webcast on 4DMT Investors website
Historical Context
-
Announced Evercore Healthcare Conference fireside chat and webcast access.
-
Appointed new CFO to lead finance and strategic initiatives.
-
Granted 45,400 RSUs to new hires under inducement plan.
-
Reported Q3 2025 results plus Otsuka deal and cash position.
-
Announced Jefferies London conference appearance and webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference. Members of the management team will also be available for one-on-one meetings.
44th Annual J.P. Morgan Healthcare Conference
| Presentation Date: | Wednesday, Jan 14, 2026 |
| Presentation Time: | 7:30 a.m. PT |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.